Associations between Self-Reported Daily Affect Ratings and Sleep Duration during the First Two Weeks of...

Area of Science:

• Psychiatry
• Sleep Medicine
• Clinical Psychology

Background:

• Major Depressive Disorder (MDD) is a prevalent condition in young adults.
• Fluoxetine is a common pharmacotherapy for MDD.
• Sleep disturbances are frequently comorbid with MDD and may impact treatment outcomes.

Purpose of the Study:

• To investigate the efficacy of a modified repeated partial sleep deprivation protocol in young adults with MDD.
• To examine if sleep duration and timing of sleep deprivation predict patient-reported affect ratings during fluoxetine treatment.
• To assess the predictive value of early affect changes on long-term treatment response.

Main Methods:

• A randomized controlled trial was conducted with 58 young adults diagnosed with DSM-IV MDD.
• Participants were assigned to either a 6-hour time in bed (TIB) or an 8-hour TIB condition for 2 weeks.
• Daily affect and sleep ratings were collected, with actigraphy used for compliance monitoring.

Main Results:

• The 6-hour TIB group showed greater improvement in negative affect and positivity ratios compared to the 8-hour TIB group.
• A 2-hour nightly bedtime delay was associated with the most significant improvements in affect.
• The trajectory of morning negative affect during the first 2 weeks predicted remission at 4 weeks.

Conclusions:

• Restricted sleep duration (6 hours TIB) may enhance early treatment response in young adults with MDD treated with fluoxetine.
• Daily monitoring of affect ratings can serve as an early indicator of treatment response.
• Sleep manipulation, specifically sleep restriction, shows promise as an adjunctive therapy for MDD.